Compounds > 1-o-hexadecyl-2-lyso-glycero-3-phosphorylcholine
Page last updated: 2024-12-08
1-o-hexadecyl-2-lyso-glycero-3-phosphorylcholine
Description
1-O-hexadecyl-2-lyso-glycero-3-phosphorylcholine (also known as **LysoPC**, **LPC**, or **Palmitoyl Lysophosphatidylcholine**) is a **phospholipid** with several important roles in research:
**Structure:**
* **Lysophospholipid:** LysoPC is a **lysolipid**, meaning it has only one fatty acid chain attached to the glycerol backbone. This differentiates it from regular phospholipids like phosphatidylcholine, which have two fatty acid chains.
* **Saturated fatty acid:** The single fatty acid tail in LysoPC is palmitic acid, a saturated fatty acid with 16 carbon atoms. This makes LysoPC less flexible and more rigid compared to other phospholipids.
**Biological Functions:**
* **Signaling molecule:** LysoPC is involved in various cellular signaling pathways, including those involved in inflammation, cell growth, and apoptosis (programmed cell death).
* **Surfactant:** LysoPC is a key component of pulmonary surfactant, a complex mixture of lipids and proteins that reduce surface tension in the lungs, facilitating breathing.
* **Lipid mediator:** LysoPC can act as a lipid mediator, influencing the activity of enzymes and receptors.
* **Cell membrane component:** LysoPC is present in cell membranes and plays a role in membrane fluidity and integrity.
**Research Importance:**
LysoPC is a crucial molecule in various research areas, including:
* **Drug development:** LysoPC's involvement in diverse biological pathways makes it a promising target for drug development. Researchers are investigating its potential role in treating various diseases, including cancer, autoimmune disorders, and lung diseases.
* **Cell biology:** LysoPC is a valuable tool for studying cell signaling, membrane dynamics, and lipid metabolism.
* **Biochemistry:** LysoPC is used in various biochemical assays and research to understand the structure and function of phospholipids.
* **Medical research:** LysoPC is investigated for its role in various diseases, including atherosclerosis, Alzheimer's disease, and sepsis.
**Overall, LysoPC is a versatile molecule with crucial functions in cell biology, signaling, and disease pathogenesis, making it a valuable subject for research.** Understanding its roles and interactions can lead to the development of new therapies and diagnostic tools.
1-O-hexadecyl-2-lyso-glycero-3-phosphorylcholine: biologically inactive precursor of platelet activating factor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
lysophosphatidylcholine O-16:0/0:0 : A lysophosphatidylcholine O-16:0e in which the hexadecyl group at C-1 contains 16 carbons of which none are unsaturated. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (50)
| Synonym |
|---|
| 1-o-hexadecyl-sn-glycero-3-phosphatidylcholine |
| 1-hexadecyl-sn-glycero-3-phosphocholine |
| 1-o-hexadecyl-sn-glycero-3-phosphocholine |
| pc(o-16:0/0:0) |
| lyso-platelet-activating factor |
| LMGP01060010 |
| 1-o-hexadecyl-sn-glyceryl-3-phosphorylcholine |
| 1-o-hexadecyl-2-lyso-sn-glycero-3-phosphocholine |
| NCGC00161374-01 |
| NCGC00161374-02 |
| NCGC00161374-03 |
| HMS1989G06 |
| 52691-62-0 |
| lyso-paf c16 |
| BML3-E04 |
| HMS1791G06 |
| 97288-09-0 |
| CHEMBL479687 |
| chebi:64496 , |
| [(2r)-3-hexadecoxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate |
| pc o-16:0/0:0 |
| lysophosphatidylcholine(o-16:0/0:0) |
| lpc o-16:0/0:0 |
| gpc(o-16:0/0:0) |
| 1-palmityl-gpc |
| lysophosphatidylcholine o-16:0/0:0 |
| lyso-gepc |
| fsf9vmh5mk , |
| 3,5,9-trioxa-4-phosphapentacosan-1-aminium, 4,7-dihydroxy-n,n,n-trimethyl-, inner salt, 4-oxide, (r)- |
| unii-fsf9vmh5mk |
| 1-o-hexadecyl-2-lyso-glycero-3-phosphorylcholine |
| lyso-platelet activating factor c16 |
| (2r)-3-(hexadecyloxy)-2-hydroxypropyl 2-(trimethylammonio)ethyl phosphate |
| LYSO-PAF C-16 , |
| 1-o-palmityl-sn-glycero-3-phosphocholine |
| HMS3648P08 |
| HMS3402G06 |
| mfcd00042932 |
| AKOS027379122 |
| lpc(o16:0) |
| c16 lyso paf, 1-o-hexadecyl-2-hydroxy-sn-glycero-3-phosphocholine, chloroform |
| c16 lyso paf, 1-o-hexadecyl-2-hydroxy-sn-glycero-3-phosphocholine, powder |
| (r)-3-(hexadecyloxy)-2-hydroxypropyl 2-(trimethylammonio)ethyl phosphate |
| Q27133319 |
| DTXSID70967131 |
| (r)-3-(hexadecyloxy)-2-hydroxypropyl (2-(trimethylammonio)ethyl) phosphate |
| CS-0181648 |
| 3,5,9-trioxa-4-phosphapentacosan-1-aminium, 4,7-dihydroxy-n,n,n-trimethyl-, inner salt, 4-oxide, (7r)- |
| (r)-3-(hexadecyloxy)-2-hydroxypropyl(2-(trimethylammonio)ethyl)phosphate |
| HY-141570 |
Roles (1)
| Role | Description |
|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
| Class | Description |
|---|
| lysophosphatidylcholine O-16:0 | A glycerophosphocholine that is sn-glycero-3-phosphocholine bearing a hexadecyl group at an unspecified position. If R1 is hexadecyl and R2 is a hydrogen then the molecule is 1-hexadecyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is hexadecyl then the molecule is 2-hexadecyl-sn-glycero-3-phosphocholine. |
| 1-alkyl-sn-glycero-3-phosphocholine | A glycerophosphocholine that consists of L-alpha-glycerophosphocholine carrying an unspecified alkyl substituent at position 1. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (10)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3
| High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID376404 | Inhibition of cholesterol biosynthesis in human chang liver cells assessed as conversion of lanosterol into cholesterol | 1999 | Journal of natural products, Nov, Volume: 62, Issue:11
| Lyso-PAF analogues and lysophosphatidylcholines from the marine sponge Spirastrella abata as inhibitors of cholesterol biosynthesis. |
| AID359760 | Cytotoxicity against human XF498 cells after 48 hrs by SRB assay | 2001 | Journal of natural products, Apr, Volume: 64, Issue:4
| Additional bioactive Lyso-PAF congeners from the sponge Spirastrella abata. |
| AID359761 | Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay | 2001 | Journal of natural products, Apr, Volume: 64, Issue:4
| Additional bioactive Lyso-PAF congeners from the sponge Spirastrella abata. |
| AID359756 | Inhibition of cholesterol biosynthesis in human Chang cells | 2001 | Journal of natural products, Apr, Volume: 64, Issue:4
| Additional bioactive Lyso-PAF congeners from the sponge Spirastrella abata. |
| AID359759 | Cytotoxicity against human SK-MEL-3 cells after 48 hrs by SRB assay | 2001 | Journal of natural products, Apr, Volume: 64, Issue:4
| Additional bioactive Lyso-PAF congeners from the sponge Spirastrella abata. |
| AID359758 | Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay | 2001 | Journal of natural products, Apr, Volume: 64, Issue:4
| Additional bioactive Lyso-PAF congeners from the sponge Spirastrella abata. |
| AID359757 | Cytotoxicity against human A549 cells after 48 hrs by SRB assay | 2001 | Journal of natural products, Apr, Volume: 64, Issue:4
| Additional bioactive Lyso-PAF congeners from the sponge Spirastrella abata. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.78
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.78 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 4.86 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |